ADAM12-L is a direct target of the miR-29 and miR-200 families in breast cancer

Abstract excerpt

BACKGROUND: ADAM12-L and ADAM12-S represent two major splice variants of human metalloproteinase-disintegrin 12 mRNA, which differ in their 3'-untranslated regions (3'UTRs). ADAM12-L, but not ADAM12-S, has prognostic and chemopredictive values in breast cancer. Expression levels of the two ADAM12 splice variants in clinical samples are highly discordant, suggesting post-transcriptional regulation of the ADAM12...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Gene expression and cancer classification
• Share to HER2/EGFR in Cancer Research
• Share to Wnt/β-catenin signaling in development and cancer